SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the second quarter of fiscal year 2017, which ended December 31, 2016.
Second quarter 2017 revenue of $483.7 million increased 6% as reported and increased 10% in constant currency from $454.9 million reported in the second quarter a year ago. For the first six months of fiscal year 2017, revenue was $925.9 million and increased 5% as reported and 9% in constant currency, compared to the $877.9 million recorded in the prior-year period. All three of the Company’s reporting segments posted constant currency revenue growth for the quarter and year-to-date period, led by strong performance within the Softgel and Drug Delivery Solutions segments.
